Serum dual-specificity phosphatase 1 reflects decreased exacerbation risk, correlates with less advanced exacerbation severity and lower inflammatory cytokines in children with asthma

Main Article Content

Xingqing Guo
Chong Wang
Dong Xie
Cui Bai
Chenggang Mao
Fang Wang

Keywords

acute exacerbation risk, asthmatic children, dual-specificity phosphatase 1, exacerbation severity, inflammatory cytokines

Abstract

Background: It is as fact that dual-specificity phosphatase 1 (DUSP1) regulates the T cell activation, pro-allergic response, and inflammation to engage with the pathogenesis of asthma, but its clinical role in children with asthma is unclear. The present study aimed to explore the expression of DUSP1, its association with exacerbation risk, severity, and inflammatory cytokines in children with asthma.


Method: Around 52 children with asthma-exacerbation, 50 children in asthma-remission, and 50 healthy children were chosen for the study. The serum levels of DUSP1, as well as tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, and IL-17 were detected by the enzyme-linked immunosorbent assay.


Results: The levels of DUSP1 was the highest in healthy children (median (IQR)=34.305 (25.892– 43.693) ng/mL), the second highest in children in asthma-remission (median (IQR)=21.471 (18.581–27.934) ng/mL), and the lowest in children with asthma-exacerbation (median (IQR)=13.982 (7.901–21.624) ng/mL) (P<0.001). At the same time, DUSP1 was also related to decreased asthma risk with area under curve (AUC) (95%CI) of 0.847 (0.780–0.914), and correlated with its lower exacerbation risk with AUC (95%CI) of 0.755 (0.661–0.849). Besides, DUSP1 was negatively linked with exacerbation severity (rs=–0.338, P=0.014), immunoglobulin E (rs=-0.277, P=0.047), TNF-α (rs=-0.423, P=0.002), IL-1β (rs=-0.389, P=0.004), and IL-17 (rs=-0.293, P=0.035), but not related with other disease features in children with asthma-exacerbation. Meanwhile, DUSP1 was only negatively associated with TNF-α (rs=-0.300, P=0.034) and IL-1β (rs=-0.309, P=0.029) in children in asthma-remission. However, no correlation was found in DUSP1 with inflammatory cytokines or other disease features in healthy children (all P>0.05).


Conclusion: DUSP1 reflects the reduced exacerbation risk, and associates with lower exacerbation severity and inflammatory cytokines in children with asthma-exacerbation; it also associates with inflammatory cytokines in children in asthma-remission. These findings suggest that DUSP1 may help to improve the management of asthmatic children.

Abstract 154 | PDF Downloads 182 HTML Downloads 13 XML Downloads 6

References

1. Papadopoulos NG, Arakawa H, Carlsen KH, Custovic A, Gern J, Lemanske R, et al. International consensus on (ICON) pediatric asthma. Allergy. 2012 Aug;67(8):976–97. 10.1111/j.1398-9995.2012.02865.x

2. Papadopoulos NG, Miligkos M, Xepapadaki P. A Current Perspective of Allergic Asthma: From Mechanisms to Management. Handb Exp Pharmacol. 2022;268:69–93. 10.1007/164_2021_483

3. Chowdhury NU, Guntur VP, Newcomb DC, Wechsler ME. Sex and gender in asthma. Eur Respir Rev. 2021 Dec 31;30(162):210067. 10.1183/16000617.0067-2021

4. Trottier ED, Chan K, Allain D, Chauvin-Kimoff L. Managing an acute asthma exacerbation in children. Paediatr Child Health. 2021 Nov;26(7):438–9. 10.1093/pch/pxab058

5. Vafaee F, Shirzad S, Shamsi F, Boskabady MH. Neuroscience and treatment of asthma, new therapeutic strategies and future aspects. Life Sci. 2022 Mar 1;292:120175. 10.1016/j.lfs.2021.120175

6. Blakey J, Chung LP, McDonald VM, Ruane L, Gornall J, Barton C, et al. Oral corticosteroids stewardship for asthma in adults and adolescents: A position paper from the Thoracic Society of Australia and New Zealand. Respirology. 2021 Dec;26(12):1112–30. 10.1111/resp.14147

7. Agusti A, Fabbri L, Lahousse L, Singh D, Papi A. Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications. Allergy. 2022 Apr;77(4):1105-13. 10.1111/all.15076

8. Rogliani P, Beasley R, Cazzola M, Calzetta L. SMART for the treatment of asthma: A network meta-analysis of real-world evidence. Respir Med. 2021 Nov;188:106611. 10.1016/j.rmed.2021.106611

9. Hoppstadter J, Ammit AJ. Role of Dual-Specificity Phosphatase 1 in Glucocorticoid-Driven Anti-inflammatory Responses. Front Immunol. 2019 Jun 26;10:1446. 10.3389/fimmu.2019.01446

10. Zhang Y, Reynolds JM, Chang SH, Martin-Orozco N, Chung Y, Nurieva RI, et al. MKP-1 is necessary for T cell activation and function. J Biol Chem. 2009 Nov 6;284(45):30815–24. 10.1074/jbc.M109.052472

11. Bluestone JA, Bour-Jordan H, Cheng M, Anderson M. T cells in the control of organ-specific autoimmunity. J Clin Invest. 2015 Jun;125(6):2250–60. 10.1172/JCI78089

12. Jeong J, Lee HK. The Role of CD4(+) T Cells and Microbiota in the Pathogenesis of Asthma. Int J Mol Sci. 2021 Oct 31;22(21):11822. 10.3390/ijms222111822

13. Golebski K, van Egmond D, de Groot EJ, Roschmann KI, Fokkens WJ, van Drunen CM. EGR-1 and DUSP-1 are important negative regulators of pro-allergic responses in airway epithelium. Mol Immunol. 2015 May;65(1):43–50. 10.1016/j.molimm.2014.12.011

14. Wancket LM, Frazier WJ, Liu Y. Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease. Life Sci. 2012 Feb 13;90(7–8):237–48. 10.1016/j.lfs.2011.11.017

15. Alam R, Gorska MM. Mitogen-activated protein kinase signalling and ERK1/2 bistability in asthma. Clin Exp Allergy. 2011 Feb;41(2):149–59. 10.1111/j.1365-2222.2010.03658.x

16. Pemmari A, Paukkeri EL, Hamalainen M, Leppanen T, Korhonen R, Moilanen E. MKP-1 promotes anti-inflammatory M(IL-4/IL-13) macrophage phenotype and mediates the anti-inflammatory effects of glucocorticoids. Basic Clin Pharmacol Toxicol. 2019 Apr;124(4):404–15. 10.1111/bcpt.13163

17. Yang M, Chen J, Wei W. Dimerization of glucocorticoid receptors and its role in inflammation and immune responses. Pharmacol Res. 2021 Apr;166:105334. 10.1016/j.phrs.2020.105334

18. Global Initiative for Asthma. Global strategy for asthma management and prevention. GINA report. Updated 2009. Available at http://www.ginasthma.com.

19. Khadir A, Kavalakatt S, Dehbi M, Alarouj M, Bennakhi A, Tiss A, et al. DUSP1 Is a Potential Marker of Chronic Inflammation in Arabs with Cardiovascular Diseases. Dis Markers. 2018;2018:9529621. 10.1155/2018/9529621

20. Zeng Y, Tao L, Ma J, Han L, Lv Y, Hui P, et al. DUSP1 and KCNJ2 mRNA upregulation can serve as a biomarker of mechanical asphyxia-induced death in cardiac tissue. Int J Legal Med. 2018 May;132(3):655–65. 10.1007/s00414-017-1616-4

21. Chang WJ, Niu XP, Hou RX, Li JQ, Liu RF, Wang Q, et al. LITAF, HHEX, and DUSP1 expression in mesenchymal stem cells from patients with psoriasis. Genet Mol Res. 2015 Dec 2;14(4):15793–801. 10.4238/2015.December.1.31

22. Theodorou J, Nowak E, Bock A, Salvermoser M, Beerweiler C, Zeber K, et al. Mitogen-activated protein kinase signaling in childhood asthma development and environment-mediated protection. Pediatr Allergy Immunol. 2022 Jan;33(1):e13657. 10.1111/pai.13657

23. Khorasanizadeh M, Eskian M, Gelfand EW, Rezaei N. Mitogen-activated protein kinases as therapeutic targets for asthma. Pharmacol Ther. 2017 Jun;174:112–26. 10.1016/j.pharmthera.2017.02.024

24. Peng HZ, Yun Z, Wang W, Ma BA. Dual specificity phosphatase 1 has a protective role in osteoarthritis fibroblastlike synoviocytes via inhibition of the MAPK signaling pathway. Mol Med Rep. 2017 Dec;16(6):8441–7. 10.3892/mmr.2017.7617

25. Moosavi SM, Prabhala P, Ammit AJ. Role and regulation of MKP-1 in airway inflammation. Respir Res. 2017 Aug 10;18(1):154. 10.1186/s12931-017-0637-3

26. Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, et al. Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. J Allergy Clin Immunol Pract. 2022 Jan;10(1S):S1-S18. 10.1016/j.jaip.2021.10.001

27. Shao LL, Gao MM, Gong JX, Yang LY. DUSP1 regulates hippo-campal damage in epilepsy rats via ERK1/2 pathway. J Chem Neuroanat. 2021 Dec;118:102032. 10.1016/j.jchemneu.2021.102032

28. Wang X, Jiang Y, Li J, Wang Y, Tian Y, Guo Q, et al. DUSP1 Promotes Microglial Polarization toward M2 Phenotype in the Medial Prefrontal Cortex of Neuropathic Pain Rats via Inhibition of MAPK Pathway. ACS Chem Neurosci. 2021 Mar 17;12(6): 966–78. 10.1021/acschemneuro.0c00567